Vesicular monoamine transporter inhibitors versus placebo for antipsychotic‐induced tardive dyskinesia
References
Additional references
Alabed S, Latifeh Y, Mohammad HA, Rifai A. Gamma‐aminobutyric acid agonists for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2011, Issue 4. [DOI: 10.1002/14651858.CD000203.pub3]
Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313(7066):1200.
American Psychiatry Association. Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association. Washington DC, 1992.
Ascher‐Svanum H, Zhu B, Faries D, Peng X, Kinon BJ, Tohen M. Tardive dyskinesia and the 3‐year course of schizophrenia: results from a large, prospective, naturalistic study. Journal of Clinical Psychiatry 2008;69(10):1580‐8.
Ballesteros J, Gonzalez‐Pinto A, Bulbena A. Tardive dyskinesia associated with higher mortality in psychiatric patients: results of a meta‐analysis of seven independent studies. Journal of Clinical Psychopharmacology 2000;20(2):188‐94.
Barnes TRE, Edwards JG. The side‐effects of antipsychotic drugs. I. CNS and neuromuscular effects. In: Barnes TRE editor(s). Antipsychotic Drugs and Their Side‐Effects. London: Academic Press/Harcourt Brace & Company, 1993.
Bergen JA, Eyland EA, Campbell JA, Jenkings P, Kellehear K, Richards A, et al. The course of tardive dyskinesia in patients on long‐term neuroleptics. British Journal of Psychiatry 1989;154(4):523‐8.
Bergman H, Walker DM, Nikolakopoulou A, Soares‐Weiser K, Adams CE. Systematic review of interventions for treating or preventing antipsychotic‐induced tardive dyskinesia. Health Technology Assessment (Winchester, England)2017; Vol. 21, issue 43:1‐218. [PUBMED: 28812541]
Bhoopathi PS, Soares‐Weiser K. Benzodiazepines for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD000205.pub2]
Bland JM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie 1999;54(4):405‐11. [PUBMED: 10667106]
Cadet JL, Lohr JB. Possible involvement of free radical in neuroleptic‐induced movement disorders. Annals of the New York Academy of Sciences 1989;570:176‐85.
Casey DE. Tardive dyskinesia: pathophysiology. In: Bloom FE, Kupfer DJ editor(s). Psychopharmacology. The Fourth Generation of Progress. New York: Raven Press, 1995.
Casey DE. Tardive dyskinesia and atypical antipsychotic drugs. Schizophrenia Research 1999;35:S61‐S66.
Cavallaro R, Regazzetti MG, Mundo E, Brancato V, Smeraldi E. Tardive dyskinesia outcomes: clinical and pharmacologic correlates of remission and persistence. Neuropsychopharmacology 1993;8(3):233‐9.
Chong SA, Tay JA, Subramaniam M, Pek E, Machin D. Mortality rates among patients with schizophrenia and tardive dyskinesia. Journal of Clinical Psychopharmacology 2009;29(1):5‐8.
Chouinard G, Chouinard VA. Atypical antipsychotics: CATIE study, drug‐induced movement disorder and resulting iatrogenic psychiatric‐like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes. Psychotherapy and Psychosomatics 2008;77(2):69‐77.
Cloud LJ, Zutshi D, Factor SA. Tardive dyskinesia: therapeutic options for an increasingly common disorder. Neurotherapeutics 2014;11(1):166‐76.
Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second‐generation antipsychotics: a systematic review of 1‐year studies. American Journal of Psychiatry 2004;161(3):414‐25.
Deeks J. Issues in the selection for meta‐analyses of binary data. 8th International Cochrane Colloquium; 2000 Oct 25‐28; Cape Town. Cape Town: The Cochrane Collaboration, 2000.
Deeks JJ, Higgins JPT, Altman DG, editor(s). Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7(6):623‐9.
Donner A, Klar N. Issues in the meta‐analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971‐80.
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ 1997;315:629‐34.
El‐Sayeh HG, Lyra da Silva JP, Rathbone J, Soares‐Weiser K. Non‐neuroleptic catecholaminergic drugs for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD000458.pub2]
Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthington HV, Vaile A. Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140‐9.
Essali A, Deirawan H, Soares‐Weiser K, Adams CE. Calcium channel blockers for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2011, Issue 11. [DOI: 10.1002/14651858.CD000206.pub3]
FDA. INGREZZA(TM) (valbenazine) capsules, for oral use; prescribing information. bit.ly/2xZkApE (accessed 22 November 2017).
Fernandez HH, Krupp B, Friedman JH. The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: 14‐year follow‐up. Neurology 2001;56(6):805‐7.
Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta‐analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(7):7‐10.
Gerlach J, Casey DE. Tardive dyskinesia. Acta Psychiatrica Scandinavica 1988;77(4):369‐78.
Glazer WM, Morgenstern H, Schooler N, Berkman CS, Moore DC. Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication. British Journal of Psychiatry 1990;157:585‐92.
Gulliford MC. Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876‐83.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327:557‐60.
Higgins JPT, Deeks JJ, editor(s). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.
Hutton JL. Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology 2009;146(1):27‐30. [PUBMED: 19438480]
Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986.
Leon AC, Mallinckrodt CH, Chuang‐Stein C, Archibald DG, Archer GE, Chartier K. Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biological Psychiatry 2006;59(11):1001‐5. [PUBMED: 16905632]
Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean?. Schizophrenia Research 2005;79(2‐3):231‐8. [PUBMED: 15982856]
Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry 2005;187:366‐71. [PUBMED: 16199797]
Leucht S, Kissling W, Davis JM. Second‐generation antipsychotics for schizophrenia: can we resolve the conflict?. Psychological Medicine 2009;39(10):1591‐602.
Lieberman JA, Fleishhacker WW. Introduction. British Journal of Psychiatry 1996;168(Suppl 29):7‐8.
Maher AR, Theodore G. Summary of the comparative effectiveness review on off‐label use of atypical antipsychotics. Journal of Managed Care Pharmacy 2012;18(5 Suppl B):S1‐20.
Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie 2005;50(9):541‐7.
Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249‐52.
Royal Pharmaceutical Society. Valbenazine. bit.ly/2jeYaLe (accessed 22/11/2017).
Royal Pharmaceutical Society. Deutetrabenazine. bit.ly/2BdrDNW (accessed 22/11/2017).
Martins ES, Rosso A, Coutinho E, Adams C, Huf G. Prevalence of tardive dyskinesia and all‐cause mortality amongst patients in a large psychiatric institute in Rio de Janeiro. Revista de Psiquiatria Clínica 2011;38:44.
Miller DD, Eudicone JM, Pikalov A, Kim E. Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis. The Journal of Clinical Psychiatry 2007;68(12):1901‐6.
Miller DD, Caroff SN, Davis SM, Rosenheck RA, McEvoy JP, Saltz BL, et al. Extrapyramidal side‐effects of antipsychotics in a randomised trial. British Journal of Psychiatry 2008;193(4):279‐88.
National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: treatment and management. Clinical guideline [CG178]. www.nice.org.uk/guidance/cg1782014.
Overall JE, Gorham DR. The brief psychiatric rating scale. Psychological Reports 1962;10:799‐812.
Rosenheck RA. Evaluating the cost‐effectiveness of reduced tardive dyskinesia with second‐generation antipsychotics. British Journal of Psychiatry 2007;191:238‐45.
Schooler NR, Keith SJ. The clinical research base for the treatment of schizophrenia. Psychopharmacology Bulletin 1993;29(4):431‐46.
Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Smith JM, Balessarini RJ. Changes in prevalence, severity and recovery in tardive dyskinesia with age. Archives of General Psychiatry 1980;37(12):1368‐73.
Soares K, McGrath J. Anticholinergic medication for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2000, Issue 2. [DOI: 10.1002/14651858.CD000204; MEDLINE: 20257419]
Soares‐Weiser K, Mobsy C, Holliday E. Anticholinergic medication for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews 1997, Issue 2. [DOI: 10.1002/14651858.CD000204]
Soares‐Weiser K, Joy C. Miscellaneous treatments for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2003, Issue 2. [DOI: 10.1002/14651858.CD000208]
Soares‐Weiser K, Rathbone J. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD000459.pub2; PUBMED: 16437425]
Soares‐Weiser K, Maayan N, McGrath J. Vitamin E for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2011, Issue 2. [DOI: 10.1002/14651858.CD000209.pub2]
Sterne JAC, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.
Tammenmaa I, McGrath J, Sailas E, Soares‐Weiser K. Cholinergic medication for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2002, Issue 3. [DOI: 10.1002/14651858.CD000207; MEDLINE: 22133093]
Tarsy D, Lungu C, Baldessarini RJ. Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. Handbook of Clinical Neurology 2011;100:601‐16.
Taylor D, Paton C, Kapur S. The Maudsley Prescribing Guidelines (10th Edition). London: Informa Healthcare, 2009.
Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area‐wide and organisation‐based intervention in health and health care: a systematic review. Health Technology Assessment 1999;3(5):1‐75.
Woods SW, Morgenstern H, Saksa JR, Walsh BC, Sullivan MC, Money R, et al. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. Journal of Clinical Psychiatry 2010;71(4):463‐74.
Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El‐Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254‐7.
![Deutetrabenazine (3R,11bR)‐3‐(2‐methylpropyl)‐9,10‐bis(trideuteriomethoxy)‐1,3,4,6,7,11b‐hexahydrobenzo[a]quinolizin‐2‐one](/cdsr/doi/10.1002/14651858.CD012986/media/CDSR/CD012986/image_n/nCD012986-AFig-FIG01.png)
Figures and Tables -
Figure 1
Deutetrabenazine (3R,11bR)‐3‐(2‐methylpropyl)‐9,10‐bis(trideuteriomethoxy)‐1,3,4,6,7,11b‐hexahydrobenzo[a]quinolizin‐2‐one
![Valbenazine (2R,3R,11bR)‐3‐isobutyl‐9,10‐dimethoxy‐1,3,4,6,7,11b‐hexahydro‐2H‐pyrido[2,1‐a]isoquinolin‐2‐yl L‐valinate)](/cdsr/doi/10.1002/14651858.CD012986/media/CDSR/CD012986/image_n/nCD012986-AFig-FIG02.png)
Figures and Tables -
Figure 2
Valbenazine (2R,3R,11bR)‐3‐isobutyl‐9,10‐dimethoxy‐1,3,4,6,7,11b‐hexahydro‐2H‐pyrido[2,1‐a]isoquinolin‐2‐yl L‐valinate)
Figures and Tables -
Figure 3
Message from one of the participants in the public and patient involvement consultation of service‐user perspectives on tardive dyskinesia research
| Interventions | Current reference(s) (updates underway) |
| Anticholinergic medication | |
| Benzodiazepines | |
| Calcium‐channel blockers | |
| Cholinergic medication | |
| Gamma‐aminobutyric acid agonists | |
| Miscellaneous treatments | |
| Antipsychotic reduction orcessation, or both, and neuroleptics | |
| Non‐neuroleptic catecholaminergic drugs | |
| Vitamin E |
Figures and Tables -
Table 1. Other Cochrane Reviews in this series
